1st Quarter - Report

ACADIA PHARMACEUTICALS for ACADIA PHARMACEUTICALS

Firm
Client
Income
—
Expenses
$440,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Implementation of the Inflation Reduction Act of 2022; Orphan Cures Act (HR 946); National Plan to End Parkinsons Act (Public Law 118-66, 118th Congress); Give Kids A Chance (HR1262); Cameron's Law (HR1414).

LobbyistCovered position, as disclosed
MICHAEL MATTOON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1262 (119th), H.R. 1414 (119th), H.R. 946 (119th)

Medicare/Medicaid MMM

Implementation of the Inflation Reduction Act of 2022; Issues related to protecting patient access to medicines in Medicare; Issues related to access to medicines for Parkinson's disease patients; Issues related to Antipsychotic use in Medicare; Orphan Cures Act (HR 946); National Plan to End Parkinsons Act (Public Law 118-66, 118th Congress); EPIC Act (HR 1492).

LobbyistCovered position, as disclosed
MICHAEL MATTOON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1492 (119th), H.R. 946 (119th)

Taxation/Internal Revenue Code TAX

Cameron's Law (HR 14114)

LobbyistCovered position, as disclosed
MICHAEL MATTOON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 14114 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.